Showing results (61-70 of 263) with videos related to
Sort By:
Pageof 27
European Urology|January 1, 1991
Growing teratoma syndrome successfully treated with lymphoblastoid interferonA van der Gaast, T C Kok, T A SplinterJournal of Cancer Research and Clinical Oncology|January 1, 1988
Levels of neuron-specific enolase after chemotherapy do not predict a response in small cell lung cancerT A Splinter, D N Carney, M Teeling, et al.European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Testing the possible non-cross resistance of two equipotent combination chemotherapy regimens against small-cell lung cancer: a phase II study of the EORTC Lung Cancer Cooperative GroupP E Postmus, E F Smit, A Kirkpatrick, et al.Cancer|February 1, 1990
Chemotherapy as treatment of choice in extrapulmonary undifferentiated small cell carcinomasA Van Der Gaast, J Verwey, E Prins, et al.Cancer|February 1, 1993
Immune-mediated thrombocytopenia secondary to suraminA D Seidman, M Schwartz, L Reich, et al.Urology|April 1, 1995
Distinguishing prognostic and treatment-predictive information for localized prostate cancerG Steineck, J Adolfsson, H I Scher, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1993
Effect of relative cumulative dose-intensity on survival of patients with urothelial cancer treated with M-VACH I Scher, N L Geller, T Curley, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1985
Methylglyoxal-bis(guanylhydrazone) in hormone-resistant adenocarcinoma of the prostateH I Scher, A Yagoda, T Ahmed, et al.Seminars in Oncology|December 1, 1992
What is the optimal dose and duration of treatment with etoposide? II. Comparative pharmacokinetic study of three schedules: 1 x 100 mg, 2 x 50 mg, and 4 x 25 mg of oral etoposide daily for 21 daysA van der Gaast, M Vlastuin, T C Kok, et al.Urology|January 1, 1996
Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancerH I Scher, Z F Zhang, D Nanus, et al.Pageof 27